Copyright © 2000 by the European Society of Cardiology.
Left ventricular outflow tract gradient decrease with non-surgical myocardial reduction improves exercise capacity in patients with hypertrophic obstructive cardiomyopathy
y
of1
mierczyk-DroszczeckaNational Institute of Cardiology, Warsaw, Poland
Received August 23, 1999; accepted August 25, 1999
Abstract
Objectives This study was undertaken to evaluate mid-term clinical results of non-surgical myocardial reduction in patients with hypertrophic obstructive cardiomyopathy.
Methods Twenty-five patients with left ventricular outflow tract obstruction (mean gradient of 84·54±31·38mmHg) and symptoms of dyspnoea, angina and/or syncope were treated with non-surgical myocardial reduction. The patients were followed-up for a mean period of 10·44±1·8 months. In all patients clinical examination with echocardiography was repeated after every 3 months of follow-up, and a symptom-limited treadmill test was repeated at the 6 month follow-up. Eighteen patients underwent simultaneous respiratory gas analysis.
Results Clinical follow-up examinations were achieved in all 25 patients. Persistent left ventricular outflow tract gradient reduction was seen in 23 patients. Seventeen patients had a reduction of left ventricular outflow tract gradient >50% of baseline value. Twenty patients showed a clinical improvement from 2·8±0·5 up to 1·2±0·5 NYHA class (P<0·001). The clinical improvement was matched by an improvement in objective measures of exercise capacity in patients with significant left ventricular outflow tract gradient reduction. Exercise time increased from 571·9±192·2 to 703·5±175·4s, P<0·001, and peak VO2increased from 14·6±5·2 to 20·5±8·6ml.kg–1min–1,P <0·05.
Conclusion Significant left ventricular outflow tract gradient reduction with exercise capacity improvement was achieved in the majority of patients treated with non-surgical myocardial reduction. We recommend this method as an alternative to surgery for symptomatic patients with hypertrophic obstructive cardiomyopathy.
Key Words: Hypertrophic obstructive cardiomyopathy, catheter therapy, exercise capacity
f1 Correspondence: W. Ru
y<<o, MD, FESC, Professor of Cardiology, Department of General Cardiology and Catheterization Laboratory, National Institute of Cardiology, Alpejska 42 Poland, 04-628 Warsaw, Poland.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. A. Malek, L. Chojnowska, M. Klopotowski, R. Maczynska, M. Demkow, A. Witkowski, B. Kusmierczyk, E. Piotrowicz, M. Konka, M. Dabrowski, et al. Long term exercise capacity in patients with hypertrophic cardiomyopathy treated with percutaneous transluminal septal myocardial ablation Eur J Heart Fail, November 1, 2008; 10(11): 1123 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S C Agarwal, I F Purcell, and S S Furniss Apical myocardial injury caused by collateralisation of a septal artery during ethanol septal ablation Heart, January 1, 2005; 91(1): e2 - e2. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. Ten Cate, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1687 - 1713. [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members, B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Eur. Heart J., November 1, 2003; 24(21): 1965 - 1991. [Full Text] [PDF]
|
|
|
|
 |
|
 E. Braunwald, C. E. Seidman, and U. Sigwart Contemporary Evaluation and Management of Hypertrophic Cardiomyopathy Circulation, September 10, 2002; 106(11): 1312 - 1316. [Full Text] [PDF]
|
|
|
|
|
|
E. D. Wigle, L. Schwartz, A. Woo, and H. Rakowski To ablate or operate? that is the question! J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1707 - 1710. [Full Text] [PDF]
|
|
|
|
|
|
R. Roberts and U. Sigwart New Concepts in Hypertrophic Cardiomyopathies, Part II Circulation, October 30, 2001; 104(18): 2249 - 2252. [Full Text] [PDF]
|
|
|
|
 |
|
 U. Sigwart Non-surgical myocardial reduction for patients with hypertrophic obstructive cardiomyopathy Eur. Heart J. Suppl., October 1, 2001; 3(suppl_L): L38 - L42. [Abstract] [PDF]
|
|
|
|
|
|
P.P. Dimitrow, D. Dudek, and J.S. Dubeil The risk of alcohol leakage into the left anterior descending coronary artery during non-surgical myocardial reduction in patients with obstructive hypertrophic cardiomyopathy. Eur. Heart J., March 1, 2001; 22(5): 437 - 437. [PDF]
|
|
|
|
|
|
H. Seggewiss Percutaneous transluminal septal myocardial ablation: A new treatment for hypertrophic obstructive cardiomyopathy Eur. Heart J., May 1, 2000; 21(9): 704 - 707. [PDF]
|
|